PROCEPT BioRobotics Corporation PRCT
As ofNov 20, 2026, 3:35 PM EST
- YTD
- -20.74%
- 1 year
- -10.60%
5D +1.90 (+8.00%)
- Market cap
- 1.44B
- Revenue (ttm)
- 352.30M
- Profit margin
- -32.60%
- EPS (ttm)
- -2.02
- Shares out
- 57.54M
- Forward P/E
- -20.69
- YTD return
- -20.74%
- 1-year return
- -10.60%
- 50-day average
- 19.67
- 200-day average
- 22.83
- Volume
- 649.11K
- Avg volume
- 1.30M
- Open
- 25.73
- Previous close
- 25.75
- Day's range
- 24.89 – 25.75
- 52-week range
- 16.67 – 38.11
- Beta
- 0.84
- Analysts
- Hold
- Price target
- 22.75 (-8.8%)
- Earnings date
- Feb 24, 2027
Key statistics
- Enterprise value
- 1.31B
- Price / sales
- 4.21
- Price / book
- 4.50
- Revenue growth
- 18.00%
- Free cash flow
- -44.44M
- Total cash
- 218.37M
- Total debt
- 76.99M
- Return on equity
- -32.39%
- Short % of float
- 14.05%
Fundamental scorecard
8 of 25 checks passed on PRCT’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 16.00
- Target (mean)
- 22.75
- Target (high)
- 30.00
- Strong buy2
- Buy3
- Hold9
- Sell0
- Strong sell1
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.2271.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -0.25 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.39152 | -0.46 | -0.07 | -17.49% |
| Aug 4, 2026 | Jun 30, 2026 | -0.46186 | -0.47 | -0.01 | -1.76% |
| Apr 29, 2026 | Mar 31, 2026 | -0.55 | -0.56 | -0.01 | -1.82% |
| Feb 25, 2026 | Dec 31, 2025 | -0.32 | -0.53 | -0.21 | -65.62% |
| Nov 4, 2025 | Sep 30, 2025 | -0.41 | -0.38 | +0.03 | +7.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Truist Securities | main | Hold | Hold |
| Nov 5, 2026 | UBS | main | Neutral | Neutral |
| Nov 5, 2026 | Leerink Partners | main | Market Perform | Market Perform |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Aug 5, 2026 | TD Cowen | main | Buy | Buy |
| Aug 5, 2026 | Piper Sandler | main | Overweight | Overweight |
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- procept-biorobotics.com
News
PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026 Truist Securities Maintains Hold on PROCEPT BioRobotics, Raises Price Target to $24
UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21
Leerink Partners Maintains Market Perform on PROCEPT BioRobotics, Raises Price Target to $22
PROCEPT BioRobotics Q3 2026 Earnings Call Transcript PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $395.409M Est
Your note
Sign in to keep a note on PRCT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DESAI ANTAL ROHIT | Director | Stock Award(Grant) | Jun 8, 2026 | 38,467 |
| HARRIS TAYLOR C | Director | Stock Award(Grant) | Jun 8, 2026 | 102,491 |
| MOLL FREDERIC H | Director | Stock Award(Grant) | Jun 8, 2026 | 866,474 |
| NOURI ALALEH | Officer | Sale | Sep 8, 2026 | 127,737 |
| SHARMA POOJA | Officer | Stock Award(Grant) | Aug 12, 2026 | 111,181 |
| SHIBLAQ HISHAM | Officer | Conversion of Exercise of derivative security | Jun 5, 2025 | 63,133 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.42% | 4,846,756 | 124.80M | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.70% | 3,276,905 | 84.38M | Sep 29, 2026 |
| BNP Paribas Asset Management Holding S.A. | 4.84% | 2,786,169 | 71.74M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.28% | 2,465,334 | 63.48M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.19% | 2,412,651 | 62.13M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 3.31% | 1,905,694 | 49.07M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 1,708,164 | 43.99M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.52% | 1,448,096 | 37.29M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2.29% | 1,318,120 | 33.94M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.15% | 1,239,150 | 31.91M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.86% | 1,072,227 | 27.61M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.24% | 711,299 | 18.32M | Jun 29, 2026 |
